WO2001079209A3 - Diazafluorenone il-8 antagonists - Google Patents

Diazafluorenone il-8 antagonists Download PDF

Info

Publication number
WO2001079209A3
WO2001079209A3 PCT/US2001/006817 US0106817W WO0179209A3 WO 2001079209 A3 WO2001079209 A3 WO 2001079209A3 US 0106817 W US0106817 W US 0106817W WO 0179209 A3 WO0179209 A3 WO 0179209A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine
mammal
diazafluorenone
human
present
Prior art date
Application number
PCT/US2001/006817
Other languages
French (fr)
Other versions
WO2001079209A2 (en
Inventor
Larry Don Bratton
David Thomas Connor
Steven Robert Miller
Bharat Kalidas Trivedi
Paul Charles Unangst
Original Assignee
Warner Lambert Co
Larry Don Bratton
David Thomas Connor
Steven Robert Miller
Bharat Kalidas Trivedi
Paul Charles Unangst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Larry Don Bratton, David Thomas Connor, Steven Robert Miller, Bharat Kalidas Trivedi, Paul Charles Unangst filed Critical Warner Lambert Co
Priority to AU2001240021A priority Critical patent/AU2001240021A1/en
Publication of WO2001079209A2 publication Critical patent/WO2001079209A2/en
Publication of WO2001079209A3 publication Critical patent/WO2001079209A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to diazafluorenone derivatives of Formula I which are IL-8 receptor antagonists useful as pharmaceutical agents, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to methods of treating a chemokine-mediated disease state in a mammal, including a human. The diazafluorenones of the present invention are useful in the treatment of chemokine-mediated diseases such as, psoriasis, cancer, asthma, Alzheimer's disease, inflammatory bowel disease, graft versus host reaction, or allograft rejections in a mammal, including a human.
PCT/US2001/006817 2000-04-13 2001-03-01 Diazafluorenone il-8 antagonists WO2001079209A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001240021A AU2001240021A1 (en) 2000-04-13 2001-03-01 Diazafluorenone il-8 receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19707300P 2000-04-13 2000-04-13
US60/197,073 2000-04-13

Publications (2)

Publication Number Publication Date
WO2001079209A2 WO2001079209A2 (en) 2001-10-25
WO2001079209A3 true WO2001079209A3 (en) 2002-05-16

Family

ID=22727926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006817 WO2001079209A2 (en) 2000-04-13 2001-03-01 Diazafluorenone il-8 antagonists

Country Status (2)

Country Link
AU (1) AU2001240021A1 (en)
WO (1) WO2001079209A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296985B1 (en) * 2000-07-06 2005-06-01 QLT Inc. Heteropolycyclic inhibitors
AU2003260072A1 (en) 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Antagonists of chemokine receptors
EP1651226B1 (en) * 2003-07-11 2010-02-24 Proteologics, Inc. Ubiquitin ligase inhibitors and methods related thereto
WO2007005403A1 (en) 2005-06-29 2007-01-11 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
EP1798232A1 (en) * 2005-12-08 2007-06-20 Hybrigenics S.A. Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
WO2007066200A2 (en) * 2005-12-08 2007-06-14 Hybrigenics Sa Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
JP5543209B2 (en) * 2006-10-30 2014-07-09 ヒブリジェニクス・エスアー Novel cysteine protease tetracycline inhibitor, its pharmaceutical composition and its use for therapy
EP1918292A1 (en) * 2006-10-30 2008-05-07 Hybrigenics S.A. Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
US7875613B2 (en) 2006-10-30 2011-01-25 Hybrigenics Sa Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
WO2012006104A2 (en) * 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
WO2018067548A1 (en) * 2016-10-03 2018-04-12 The Children's Medicial Center Corporation Prevention and treatment of diabetic nephropathy
JP2023549565A (en) * 2020-11-18 2023-11-27 テキサス・テック・ユニバーシティー・システム Cancer treatment using small molecules that bind to and inhibit ral-interacting proteins
WO2023225558A1 (en) * 2022-05-17 2023-11-23 Avesta76 Therapeutics, Inc. Inhibitors of rlip76

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042464A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company SUBSTITUTED IMIDAZO[1,2-a;3,4-a']DIQUINOLINYLIUM INTERLEUKIN-8 RECEPTOR ANTAGONISTS
WO1999042463A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042464A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company SUBSTITUTED IMIDAZO[1,2-a;3,4-a']DIQUINOLINYLIUM INTERLEUKIN-8 RECEPTOR ANTAGONISTS
WO1999042463A1 (en) * 1998-02-23 1999-08-26 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

Also Published As

Publication number Publication date
AU2001240021A1 (en) 2001-10-30
WO2001079209A2 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
IL173396A0 (en) Piperazine derivatives and their use as therapeutic agents
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
WO2001042231A3 (en) Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors
WO2001079209A3 (en) Diazafluorenone il-8 antagonists
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
EP2266569A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2002080846A3 (en) Epothilone derivatives and methods for making and using the same
HUP9900950A3 (en) Use of nicotine derivatives for producing pharmaceutical compositions suitable for treating inflammatory bowel disease
WO2006086447A3 (en) Pyridazine derivatives and their use as therapeutic agents
HK1074046A1 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
MX9703518A (en) Dihydropyrimidines and uses thereof.
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
TNSN04165A1 (en) Substituted hydroxyethylamines
MXPA04003439A (en) 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists.
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
WO1998051311A3 (en) Dihydropyrimidines and uses thereof
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
CA2468649A1 (en) Adenosine a2a receptor antagonists
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP